Cannabinoids may provide a treatment option for prostate cancer that has become nonresponsive to common therapy, according to a study published in the February issue of the journal Oncology Reports, and published online this week by the National Institute of Health.
According to researchers; “In the early stages, prostate cancer is androgen‑ dependent; therefore, medical castration has shown significant results during the initial stages of this pathology. Despite this early effect, advanced prostate cancer is resilient to such treatment.”
They continue; “Recent evidence shows that derivatives of Cannabis sativa and its analogs may exert a protective effect against different types of oncologic pathologies. The purpose of the present study was to detect the presence of cannabinoid receptors (CB1 and CB2) on cancer cells with a prostatic origin and to evaluate the effect of the in vitro use of synthetic analogs.”
After conducting the study using “commercial cell line and primary cultures derived from prostate cancer and benign prostatic hyperplasia”, researchers found that “endocannabinoids may be a beneficial option for the treatment of prostate cancer that has become nonresponsive to common therapies.”
The study was conducted by researchers at the University of Chile, and can be found by clicking here.